吉西他滨联合奥沙利铂治疗晚期复发上皮性卵巢癌的临床疗效及不良反应  

Clinical efficacy and adverse reactions of gemcitabine combined with oxaliplatin in the treatment of advanced recurrent epithelial ovarian cancer

作　　者：郭志军[1] 

机构地区：[1]河北省唐山市丰润区人民医院肿瘤放化疗中心,唐山064000

出　　处：《中国肿瘤临床与康复》2016年第2期212-214,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨吉西他滨联合奥沙利铂治疗晚期复发上皮性卵巢癌患者的临床疗效及不良反应。方法选取2010年7月至2014年4月间收治的确诊为晚期复发上皮性卵巢癌的68例患者,按照随机数字表法分为TG组(35例)和CG组(33例)。TG组患者采用吉西他滨联合奥沙利铂,CG组患者采用奥沙利铂。比较两组患者的临床效果及不良反应。结果 TG组中,完全缓解(CR)12例,部分缓解(PR)10例,疾病稳定(SD)8例,疾病进展(PD)5例,有效率为62.9%;CG组中,CR 5例,PR 9例,SD 5例,PD 14例,有效率为42.4%,组间差异有统计学意义(P<0.05)。TG组患者生活质量评价量表(SF-36)评分治疗前、后分别为(47.17±10.14)分和(64.80±9.31)分,差异有统计学意义(P<0.01),而且治疗后、TG组SF-36评分高于CG组的(54.32±15.56)分,差异有统计学意义(P<0.05)。TG组中共有5例(14.3%)患者出现不良反应,其中Ⅰ度3例,Ⅱ度1例,Ⅲ度1例;CG组中共有12例(36.4%)患者出现不良反应,其中Ⅰ度3例,Ⅱ度4例,Ⅲ度4例,Ⅳ度1例,组间比较差异有统计学意义(P<0.05)。结论吉西他滨联合奥沙利铂治疗晚期复发上皮性卵巢癌的临床疗效确切,副作用少,值得临床推广应用。Objective To investigate the clinical efficacy and adverse reactions of gemcitabine combined with oxaliplatin （TG） in the treatment of advanced recurrent epithelial ovarian cancer pa- tients. Methods From July 2010 to April 2014 in Fengrun Distract People＇s Hospital, 68 recurrent epithe- lial ovarian cancer patients were enrolled in the study and randomly divided into treatment group （TG, n = 35 ） and control group （CG, n = 33 ）. The patients in TG group accepted gemcitabine combined with oxali- platin treatment and those in the CG group only acceped oxaliplatin. The clinical efficacy and adverse reac- tions between the two groups were compared. Results After treatment, the effective rate was 62. 9% in TG group, and the effective rate was 42. 4% in CG group, with significant difference （ P 〈 0. 05 ）. Short form 36 questionnaire （SF-36） scores were significantly improved from （47.17 ± 10. 14） to （64.80 ±9.31 ） in TG group （P 〈0.01 ）, and significantly higher than the score （54. 32 ± 15.56） of CG group（P 〈0. 05）. A total of 5 cases （ 14. 3% ） had side effects in TG group, including 3 cases of grade Ⅰ, 1 case of grade Ⅱ1 case of grade Ⅲ; and a total of 12 cases （36. 4% ） had side effects in CG group, including 3 cases of grade Ⅰ, 4 cases of grade Ⅱ, 4 cases of grade Ⅲ, 1 ease of grade Ⅳ, showed significant differences （P 〈0. 05）. Conclusion Gemeitabine combined with oxaliplatin showed obvious clinical efficacy in the treatment of advanced recurrent epithelial ovarian cancer and less side effects. It should be widely applied.

关 键 词：卵巢上皮肿瘤 药物疗法 治疗结果 

分 类 号：R737.31[医药卫生—肿瘤]